The introduction of first-generation drugeluting stents (DES) was a major advance in the percutaneous treatment of coronary artery disease, with DES significantly reducing the incidence of restenosis and major adverse coronary events compared with bare metal 
INTRODUCTION
Drug-eluting stents (DES) have not only improved clinical outcomes compared with bare metal stents (BMS), they have vastly enhanced our capability and confidence to tackle increasingly complex patients and lesions traditionally treated with coronary artery bypass graft surgery (CABG) [1] [2] [3] . This has in turn increased percutaneous coronary interventional (PCI) procedural volumes worldwide and DES use in clinical and angiographic scenarios not initially tested and approved by the U.S. Food and Drug Administration (FDA), otherwise referred to as off-label use. The result has been justifiable concerns regarding the efficacy and associated risk of DES in these situations. However, these concerns have been continually addressed by carefully collected outcomes analyses from large longitudinal registries, data from randomized controlled trials (RCTs), and translational research studies combined with advances in DES technology. Importantly, this effort has been a result of unprecedented collaboration between regulatory bodies, industry, and the interventional community.
In this review, the clinical outcome data of the most recently FDA-approved DES are critically examined, the Resolute TM zotarolimus-eluting stent (R-ZES, Medtronic, Inc., Santa Rosa, CA, USA), and the unique features of the next iteration of the R-ZES built on the Integrity TM platform (Medtronic, Inc., Santa Rosa, CA, USA) to further enhance stent flexibility and deliverability, especially in complex lesions. [11] . There is an initial release of zotarolimus from the surface of the stent followed by extended drug elution. Nearly 85% of the zotarolimus (dose density *1.6 lg/ mm 2 ) is released by 60 days, and completely by 180 days [11] .
R-ZES
The thin strut, low profile, and continuous sinusoidal design combined with the biocompatible polymer and extended drug release is designed to maximize deliverability and efficacy of this new generation R-ZES. However, the evidence regarding its long-term safety for complex patient subsets also needs to be critically examined. This review will summarize the clinical data for the R-ZES and discuss results in the context of complex ''realworld'' PCI.
METHODS
The PubMed database was used to identify all prospective clinical trials for the R-ZES and the everolimus-eluting stent (EES) for the past 
R-ZES CLINICAL STUDIES
The first-in-man R-ZES experience (RESOLUTE study) was a 139 patient, multicenter, prospective study examining 9-month in-stent late loss and target lesion revascularization (TLR) in stenotic de novo lesions in coronary vessels with reference vessel diameter between 2.5 and 3.5 mm in diameter and 14 mm to 27 mm in length [12] . The study required a 4-month angiographic and intra-vascular ultrasound (IVUS) follow-up in the first 30 patients and a 9-month follow-up in the remainder. Complex patients with recent and EES groups (P value for interaction = 0.14) [17] .
Prespecified 2-year clinical outcomes of the R-AC trial demonstrated sustained safety and efficacy for the R-ZES and EES [18] . The rates of TLF at 3 years were 13.1% for R-ZES and 12.4%
for EES (P = 0.614). Additionally, the rates of definite or probable ST at 3 years were also low [19] . Rates of definite or probable very late stent thrombosis (VLST) were 0.5% for both stents. DAPT use was 84.4 and 83.5% at 1 year for the R-ZES and EES groups, respectively (P = 0.60).
The RESOLUTE International Trial (R-Int) trial enrolled an unrestricted cohort of 2,349 patients, two-thirds of which were complex with at least one R-ZES (2.25-4.0 mm stent diameter). Nearly 30% of patients were diabetic and 46% presented with an acute coronary syndrome (ACS). The composite primary endpoint of cardiac death and target vessel MI at 1 year was 4.3% [20] .
The pooled RESOLUTE clinical program derived from five R-ZES studies (RESOLUTE, R-US, R-AC, R-Int and RESOLUTE Japan) includes 5,130 patients [21] . Nearly 30% of patients had DM and 46% were complex. The diabetic cohort was older with expectedly more patients with hypertension, hyperlipidemia, or prior PCI. At 2 years, clinically-driven TLR was 4.7% and definite or probable ST was 0.9%. In a prespecified analysis of less complex patients with DM, 2-year rates of clinically-driven TLR and definite or probable ST for patients with DM (n = 861) was 4.8% and 0.3%, respectively (Fig. 1) [21] . In the nondiabetic cohort (n = 1,903) these 2-year endpoints were reached in 3.4% and 0.4% patients, respectively. These data indicate consistently low event rates and durable clinical outcomes in the higher-risk patients with DM. Based on these data the R-ZES is the first DES approved by the FDA for use in patients with DM.
The diabetic population included 29.6% of patients with insulin-dependent DM. At 1 year, event rates were significantly higher in patients with insulin-dependent diabetes mellitus IDDM compared with those without DM (TLR 6.3% vs. [22]. The cumulative incidence of TLF, cardiac Fig. 1 Two-year event rates for standard-risk patients with diabetes mellitus (n = 861) in the pooled RESOLUTE global clinical program [21] ST stent thrombosis, TLF target lesion failure, TLR target lesion revascularization, TVF target vessel failure, TVMI target vessel myocardial infarction death, target vessel MI, and TLR was similar for DM patients receiving the R-ZES (7.8%) and the EES (9.0%) at 1 year (P = 0.96); there was a trend to lower TLF in the non-DM patients (R-ZES 6.1%; EES 8.3%; [P = 0.09]). One year outcomes for R-ZES and EES DM patients were also similar for rates of TLR, cardiac death or MI, and ST [22] . These data also indicate to the strength of the RESOLUTE pooled clinical program which was conceptualized using similar event definitions, adjudication, and data management methodology across a myriad of R-ZES trials. It is imperative that data from this large and diverse cohort of patients representing a ''real-world'' patient population will continue to be the source of important data and guide contemporary PCI practice worldwide. Overall, there was no long-term increase in death with any of the DES [26] . In the R-AC trial, R-ZES was associated with a higher definite stent thrombosis at 1 year than EES (1.2% vs. 0.3%; [P = 0.01]), while definite or probable stent thrombosis at 2 years were 1.9% and 1.0%
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(P = 0.08) for R-ZES and EES, respectively [16, 18] However, in the TWENTE trial, definite or probable ST rates for R-ZES and EES were 0.9% and 1.2%, respectively (P = 0.59). Definite ST rates were also low (0.58% and 0%, respectively
[P = 0.12]) [27] . Comparative data of ST across R-ZES and EES studies is shown in Fig. 2 [16, 20, 25, [27] [28] [29] [30] [31] [32] [33] [34] . It is important to note that these data are not based on direct comparisons and on studies not powered for the low frequency ST event. These data suggest a very low risk of ST with R-ZES and EES stents and the observed differences are caused by chance. Patti et al. [35] reported in a 2008 metaanalysis of nine studies comparing DES with BMS in DM patients, including 1,141 patients, an in-stent restenosis (ISR) and TLR rates with BMS of 41% and 27%, significantly higher than first generation DES ISR and TLR rates of 8% and 8%, respectively (P\0.0001 for both comparisons). In a pooled analysis of EES versus paclitaxel-eluting stent from the SPIRIT and COMPARE trials, ischemia-driven TLR rates were 6.1% and 5.5% for diabetics in the paclitaxel-eluting and EES recipients, respectively (P = 0.60); it was 6.9% and 3.6%, respectively in nondiabetics (P\0.0001) [36] . In a more recent all-comer DES study presented by Jensen et al., TVR rates in patients with DM with sirolimus-eluting stent and EES were 10.7% and 6.7% at 18 months, respectively [37] . While this subgroup analysis was not powered to assess these endpoints, these data support the observation that significant strides have been made with respect to PCI outcomes in diabetics with complex coronary artery disease revascularized percutaneously with R-ZES. 
